Thubrikar Aortic Valve develops a next-generation Transcatheter Aortic Valve Implantation (TAVI) device and delivery catheter called the Optimum TAVI System, designed after the natural valve based on 30 years of research by Founder Dr. Mano Thubrikar. The Optimum TAV and its PRECISION CATHETER are specific to the system and will be available in multiple sizes. The company has a 2014 license agreement with Labcor for clinical testing, manufacturing, and South America sales; ANVISA has granted Labcor permission to start a clinical trial expected in 2018. Thubrikar also has a license agreement with Wide Line Limited for China, with a clinical trial expected in 2019. The company has applied to Health Canada to sponsor its own First‑In‑Human study toward European approval. Financially, Thubrikar closed an interim financing that included cash and a promissory note totaling $1.0M, and Wide Line is identified as the company's largest investor to date. The company is based in Norristown, PA.

Total raised

$1M

Funding rounds

2

Latest round

Convertible Note

Latest activity

Jul 2018